BiotechTube

ARS-1 + Albuterol MDI + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Jul 28, 2022 → Feb 2, 2024

NCT ID
NCT05363670

About ARS-1 + Albuterol MDI + Placebo

ARS-1 + Albuterol MDI + Placebo is a phase 2 stage product being developed by ARS Pharmaceuticals for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT05363670. Target conditions include Asthma.

What happened to similar drugs?

20 of 20 similar drugs in Asthma were approved

Approved (20) Terminated (1) Active (0)
✅DuleraMerckApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅levalbuterol HCl + albuterol SulfateSumitomo PharmaApproved
✅arformoterol (RR formoterol) + placebo + levalbuterolSumitomo PharmaApproved
✅Racemic albuterol (R+S albuterol) + Levalbuterol (R albuterol)Sumitomo PharmaApproved
✅BenralizumabAstraZenecaApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05363670Phase 2Completed

Competing Products

20 competing products in Asthma

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
40
DuleraMerckApproved
43
BriquilimabJasper TherapeuticsPhase 1
11
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
35
RoflumilastAstraZenecaPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
35
Regadenoson + PlaceboAstellas PharmaApproved
43
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
40
rabeprazoleEisaiPhase 3
40
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
Placebo + BrodalumabKyowa KirinPhase 2
27
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
35
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40